Comparing Jupiter Neurosciences (NASDAQ:JUNS) & Eloxx Pharmaceuticals (NASDAQ:ELOX)

Jupiter Neurosciences (NASDAQ:JUNS) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Insider and Institutional Ownership

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 38.6% of Jupiter Neurosciences shares are held by insiders. Comparatively, 25.9% of Eloxx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Jupiter Neurosciences and Eloxx Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jupiter Neurosciences	N/A	-1,314.62%	-246.66%
Eloxx Pharmaceuticals	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for Jupiter Neurosciences and Eloxx Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jupiter Neurosciences	1	0	0	0	1.00
Eloxx Pharmaceuticals	1	0	2	2	3.00

Eloxx Pharmaceuticals has a consensus target price of $38.33, indicating a potential upside of 148.27%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Eloxx Pharmaceuticals is more favorable than Jupiter Neurosciences.

Risk & Volatility

Jupiter Neurosciences has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals has a beta of -1862.26, indicating that its share price is 186,326% less volatile than the S&P 500.

Earnings & Valuation

This table compares Jupiter Neurosciences and Eloxx Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jupiter Neurosciences	$20,000.00	135.13	-$8.65 million	($19.12)	-0.16
Eloxx Pharmaceuticals	$6.36 million	9.81	-$5.99 million	($1.54)	-10.03

Eloxx Pharmaceuticals has higher revenue and earnings than Jupiter Neurosciences. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Eloxx Pharmaceuticals beats Jupiter Neurosciences on 10 of the 14 factors compared between the two stocks.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.